RenovoRx (RNXT) Stock Price, News & Analysis

Company Overview

RenovoRx, Inc. is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors. By leveraging a patented catheter design, the system enables localized drug perfusion through arterial infusion, potentially enhancing tumor uptake of chemotherapeutic agents. RenovoRx has also entered strategic collaborations to advance its clinical programs, including licensing arrangements for development and commercialization in select international markets.

Headquartered in Little Silver, New Jersey, RenovoRx conducts its clinical development activities through a network of investigative sites across the United States. The company’s management team comprises seasoned professionals with experience in interventional oncology, medical device development and regulatory affairs. As a Nasdaq-listed entity trading under the symbol RNXT, RenovoRx continues to advance its pipeline toward pivotal studies with the goal of offering new treatment options for patients with limited therapeutic alternatives.

Key Stats

• Today's Range: $0.87 to $0.92
• 50-Day Range: $0.78 to $1.16
• 52-Week Range: $0.70 to $1.45
• Volume: 331,951 shs
• Average Volume: 305,017 shs
• Market Capitalization: $40.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Moderate Buy

RenovoRx Stock Analysis - MarketRank™

RenovoRx scored higher than 86% of companies evaluated by MarketBeat, and ranked 100th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

RenovoRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

RenovoRx has a consensus price target of $8.50, representing about 838.6% upside from its current price of $0.91.

Amount of Analyst Coverage

RenovoRx has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for RenovoRx are expected to grow in the coming year, from ($0.30) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of RenovoRx is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of RenovoRx is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

RenovoRx has a P/B Ratio of 6.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.94% of the float of RenovoRx has been sold short.

Short Interest Ratio / Days to Cover

RenovoRx has a short interest ratio ("days to cover") of 1.44, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RenovoRx has recently decreased by 24.09%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RenovoRx does not currently pay a dividend.

Dividend Growth

RenovoRx does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.84

News Sentiment

RenovoRx has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for RenovoRx this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for RNXT on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

3 people have added RenovoRx to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 3.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $19,750.00 in company stock, which represents 0.0484% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, RenovoRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,750.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

9.13% of the stock of RenovoRx is held by insiders.

Percentage Held by Institutions

3.10% of the stock of RenovoRx is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/03/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNXT
• CIK: 1574094
• Web: www.renovorx.com
• Phone: 650-284-4433
• Fax: 650-397-4433
• Employees: 6
• Year Founded: 2012

Price Target and Rating

• Average Price Target for RenovoRx: $8.50
• High Price Target: $14.00
• Low Price Target: $3.00
• Potential Upside/Downside: +838.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.17 million
• Net Margins: -823.98%
• Pretax Margin: -823.98%
• Return on Equity: -135.03%
• Return on Assets: -101.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.15
• Quick Ratio: 6.95

Sales & Book Value

• Annual Sales: $1.12 million
• Price / Sales: 36.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 6.04

Miscellaneous

• Outstanding Shares: 45,100,000
• Free Float: 40,981,000
• Market Cap: $40.84 million
• Optionable: Not Optionable
• Beta: 1.01